Q3 2026 Cohance Lifesciences Ltd Earnings Call Transcript
Key Points
- Cohance Lifesciences Ltd (BOM:543064) has deepened customer engagement with two large global innovators, progressing multiple ongoing programs and new RFPs.
- The company supports a robust late-stage pipeline with 9 Phase III programs, providing medium-term visibility as these assets progress towards launch and scale-up.
- Cohance Lifesciences Ltd has secured a commercial KSM opportunity with a Spec Chem CDMO, with commercial supplies expected to commence from the second half of FY'27.
- The company has onboarded two highly seasoned business development professionals to support increasing engagement in higher complexity oligonucleotides and amidite programs.
- The specialty chemicals segment reported a revenue growth of 32% YoY, driven by customer diversification and pipeline development.
- Cohance Lifesciences Ltd's recent performance has come in below expectations, with FY'26 being a transition year due to portfolio mix and customer-led timing factors.
- The Nacharam formulation site received a warning letter, impacting production and leading to shipment deferrals of approximately INR55 crores.
- The company experienced a revenue decline of 6.7% for the nine months of FY'26, influenced by de-stocking in two large commercial products and customer-related approval delays.
- Near-term revenues were impacted by customer-led delays in reloads and payload intermediate offset, driven by higher inventory levels and changes in launch timing.
- The API+ segment reported a revenue decline of 8% year on year, affected by regulatory and demand-related factors.
Ladies and gentlemen, good day and welcome to Q3 and nine months FY'26 earnings conference call of Cohance Lifesciences Limited. (Operator Instructions). Please note that this conference is being recorded.
And now in the conference Cyndrella Carvalho. Thank you and over to you, ma'am.
Thanks, Neerav. Good evening. Good morning, everyone, and thank you for joining Cohance Lifesciences earnings calls for the third quarter and nine months of FY'26.
Joining me today we have our Executive Chairman Mr. Vivek Sharma. Mr. Yann D'herve, CEO of Pharma CDMO, Mr. Gunjan Singh, Business Head - API+, Mr. Amrit Singh, Business Head - Specialty Chemicals, and our Whole-time Director and Chief Financial Officer, Mr. Himanshu.
Before we begin, I would like to remind you that today's discussion may include forward-looking statements which are subject to risk and uncertainty. Actual results may differ materially. We encourage you to review the disclosures filed by the company.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
